RGBP — Regen BioPharma Balance Sheet
0.000.00%
- $0.73m
- $1.77m
- $0.24m
Annual balance sheet for Regen BioPharma, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0 | 0.727 | 0.051 | 0.121 | 0.001 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.103 | 0.219 | 0.254 | 0 | 0.095 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.103 | 0.994 | 0.336 | 0.131 | 0.143 |
| Long Term Investments | |||||
| Total Assets | 0.123 | 1.21 | 0.559 | 0.354 | 0.161 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.46 | 14.7 | 8.6 | 5.31 | 5.38 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.46 | 14.7 | 8.6 | 5.46 | 5.38 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -7.33 | -13.5 | -8.04 | -5.1 | -5.22 |
| Total Liabilities & Shareholders' Equity | 0.123 | 1.21 | 0.559 | 0.354 | 0.161 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |